LABCORP HOLDINGS INC（LH）の決算・業績分析
LABCORP HOLDINGS INCの2025年有価証券報告書をAI分析。売上高$14.0B(+7.2%)。営業利益$1.4B。Health Care。
目次
LABCORP HOLDINGS INCの2025年度 業績サマリー
LABCORP HOLDINGS INC（証券コード: LH）の2025年度決算・業績分析。売上高は$14.0B（前年比+7.2%）。営業利益は$1.4B（前年比+27.4%）。純利益は$876M（前年比+17.5%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
LABCORP HOLDINGS INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue declined 9.7% YoY to $11.9B (XBRL), driven by lower operating income from Dx and BLS segments and reduced COVID-19 Testing (10-K).
- Operating income fell 52.9% YoY to $1.4B (XBRL), with SG&A expenses rising 10.3% to $2.23B (10-K).
- Net income dropped 46.2% YoY to $1.3B (XBRL), despite $1.3B returned to shareholders via dividends and share repurchases (XBRL).
- Net debt stood at $3.7B (1.9x EBITDA) (XBRL), with equity ratio at 61.4% (XBRL).
- Cash flow from operations was $2.0B (XBRL), but CapEx of $429M (XBRL) reduced free cash flow to $1.5B.
LABCORP HOLDINGS INCの売上高変化の要因
- •Total revenue was $11.9B (XBRL), a -9.7% YoY decline. Dx segment revenue was $10,144.3M (10-K), while BLS segment revenue was $2,922.6M (10-K). The decline was attributed to lower operating income from both segments and reduced demand for COVID-19 Testing (10-K). The 10-K text mentions a conflicting 7.0% YoY increase to $13.0B, but XBRL data confirms the $11.9B figure (10-K).
LABCORP HOLDINGS INCの営業利益変化の要因
- •Gross profit was $3.7B (XBRL) with a 31.3% margin (XBRL). Operating income fell 52.9% YoY to $1.4B (XBRL), with SG&A expenses rising 10.3% YoY to $2.23B (10-K). Net income declined 46.2% YoY to $1.3B (XBRL), impacted by goodwill impairment ($5.3M) and higher amortization ($256.4M) (XBRL). Gross margin improved slightly to 31.3% (XBRL) due to higher organic demand and cost savings, despite a 6.7% YoY increase in cost of revenue (10-K).
LABCORP HOLDINGS INCの事業リスクと対応
Economic and geopolitical factors could reduce demand for diagnostic services and disrupt operations (10-K).
Government budget changes and credit market volatility may impact funding and financing (10-K).
Natural disasters, geopolitical events, or public health crises could disrupt operations and testing volumes (10-K).
Difficulty retaining qualified personnel may harm business and increase costs (10-K).
Changes in healthcare reimbursement models and payer mix could reduce revenues and profitability (10-K).
LABCORP HOLDINGS INCの今後の見通し・業績予想
LABCORP HOLDINGS INCの事業内容
Labcorp provides diagnostic testing (routine and specialty) and biopharma laboratory services (early development research and central lab services) to healthcare stakeholders (10-K). The company operates through two primary segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS) (10-K). With nearly 70,000 employees (10-K), Labcorp leverages science/technology innovation, global scale, and data analytics as competitive advantages (10-K). Key customers include doctors, hospitals, pharmaceutical companies, researchers, and patients, with no significant customer concentration (10-K).
LABCORP HOLDINGS INCのAI業績分析レポート（2024年度）
Labcorp Holdings Inc. (LH) FY2024 Annual Report Analysis
Highlights
Business Overview
Labcorp provides diagnostic testing (routine and specialty) and biopharma laboratory services (early development research and central lab services) to healthcare stakeholders (10-K). The company operates through two primary segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS) (10-K). With nearly 70,000 employees (10-K), Labcorp leverages science/technology innovation, global scale, and data analytics as competitive advantages (10-K). Key customers include doctors, hospitals, pharmaceutical companies, researchers, and patients, with no significant customer concentration (10-K).
Revenue Analysis
Total revenue was $11.9B (XBRL), a -9.7% YoY decline. Dx segment revenue was $10,144.3M (10-K), while BLS segment revenue was $2,922.6M (10-K). The decline was attributed to lower operating income from both segments and reduced demand for COVID-19 Testing (10-K). The 10-K text mentions a conflicting 7.0% YoY increase to $13.0B, but XBRL data confirms the $11.9B figure (10-K).
Profitability Analysis
Gross profit was $3.7B (XBRL) with a 31.3% margin (XBRL). Operating income fell 52.9% YoY to $1.4B (XBRL), with SG&A expenses rising 10.3% YoY to $2.23B (10-K). Net income declined 46.2% YoY to $1.3B (XBRL), impacted by goodwill impairment ($5.3M) and higher amortization ($256.4M) (XBRL). Gross margin improved slightly to 31.3% (XBRL) due to higher organic demand and cost savings, despite a 6.7% YoY increase in cost of revenue (10-K).
Balance Sheet Analysis
Equity ratio was 61.4% (XBRL), with total debt at $4.1B (XBRL) and net debt at $3.7B (1.9x EBITDA) (XBRL). Current ratio was 1.17x (XBRL), and cash reserves stood at $321M (XBRL). Long-term debt was $4.1B (XBRL), but maturity profile details were not disclosed (XBRL).
Cash Flow Analysis
Operating cash flow was $2.0B (XBRL), higher than net income ($1.3B) due to non-cash expenses (XBRL). Free cash flow was $1.5B (XBRL), calculated as $2.0B operating cash flow minus $429M CapEx (XBRL). Investing cash flow was -$1.7B (XBRL), while financing cash flow was -$1.3B (XBRL), reflecting $195M in dividends and $1.1B in share repurchases (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) was 43 days (XBRL), with receivables days at 59, inventory days at 21, and payables days at 37 (XBRL).
Risks
Outlook
Management did not provide explicit guidance for FY2025 (N/A). Key trends include declining operating income, higher SG&A expenses, and reduced revenue from COVID-19 Testing (10-K).
Health Careの企業一覧
LABCORP HOLDINGS INCと同じ「Health Care」セクターの企業